170 related articles for article (PubMed ID: 28608784)
1. Suppressed MMP-9 Activity in Myocardial Infarction-Related Cardiogenic Shock Implies Diminished Rage Degradation.
Selejan SR; Hewera L; Hohl M; Kazakov A; Ewen S; Kindermann I; Böhm M; Link A
Shock; 2017 Jul; 48(1):18-28. PubMed ID: 28608784
[TBL] [Abstract][Full Text] [Related]
2. Role of receptor for advanced glycation end products in cardiogenic shock.
Selejan SR; Pöss J; Hewera L; Kazakov A; Böhm M; Link A
Crit Care Med; 2012 May; 40(5):1513-22. PubMed ID: 22430238
[TBL] [Abstract][Full Text] [Related]
3. Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock.
Selejan S; Pöss J; Walter F; Hohl M; Kaiser R; Kazakov A; Böhm M; Link A
Eur Heart J; 2012 May; 33(9):1085-94. PubMed ID: 21998404
[TBL] [Abstract][Full Text] [Related]
4. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome.
Selejan SR; Linz D; Tatu AM; Hohl M; Speer T; Ewen S; Mahfoud F; Kindermann I; Zamyatkin O; Kazakov A; Laufs U; Böhm M
J Mol Cell Cardiol; 2018 Sep; 122():34-46. PubMed ID: 30096408
[TBL] [Abstract][Full Text] [Related]
5. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Matrix Metalloproteinase-9 Protects against Sepsis-Induced Acute Lung Injury via Promoting the Release of Soluble Receptor for Advanced Glycation End Products.
Zhang H; Mao YF; Zhao Y; Xu DF; Wang Y; Xu CF; Dong WW; Zhu XY; Ding N; Jiang L; Liu YJ
Oxid Med Cell Longev; 2021; 2021():8889313. PubMed ID: 33628393
[TBL] [Abstract][Full Text] [Related]
7. Circulating soluble RAGE and cell surface RAGE on peripheral blood mononuclear cells in healthy children.
García-Salido A; Melen G; Gómez-Piña V; Oñoro-Otero G; Serrano-González A; Casado-Flores J; Ramírez M
J Pediatr Endocrinol Metab; 2018 Jun; 31(6):649-654. PubMed ID: 29723156
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):53-61. PubMed ID: 15782494
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction.
Yasuda S; Miyazaki S; Kinoshita H; Nagaya N; Kanda M; Goto Y; Nonogi H
Clin Sci (Lond); 2007 Jan; 112(1):43-9. PubMed ID: 16939410
[TBL] [Abstract][Full Text] [Related]
10. Regadenoson Reduces Soluble Receptor for Advanced Glycation End-Products in Lung Recipients.
Zhao Y; Dhru U; Fleischmann E; Mostafa E; Al-Suqi M; Conaway MR; Krupnick AS; Linden J; Rabin J; Lau CL
Ann Thorac Surg; 2023 Dec; 116(6):1150-1158. PubMed ID: 36921749
[TBL] [Abstract][Full Text] [Related]
11. Acute myocardial infarction is reflected in salivary matrix metalloproteinase-8 activation level.
Buduneli E; Mäntylä P; Emingil G; Tervahartiala T; Pussinen P; Barış N; Akıllı A; Atilla G; Sorsa T
J Periodontol; 2011 May; 82(5):716-25. PubMed ID: 21091346
[TBL] [Abstract][Full Text] [Related]
12. [Effects of doxycycline on the expression of matrix metalloproteinase and tissue inhibitor of MMP in myocardium after acute myocardial infarction: an animal experiment with rats].
Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1288-93. PubMed ID: 15387968
[TBL] [Abstract][Full Text] [Related]
13. [Dynamics of interleukin 6 levels in the patients with cardiogenic and septic shock and in a control group of patients with uncomplicated AMI].
Pařenica J; Maláska J; Jarkovský J; Helánová K; Jabandžiev P; Michálek J; Veselková Z; Littnerová S; Kubková L; Gál R; Sevčík P; Goldbergová MP; Litzman J; Čermáková Z; Špinar J
Vnitr Lek; 2014 Feb; 60(2):114-22. PubMed ID: 24754415
[TBL] [Abstract][Full Text] [Related]
14. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction.
Park HJ; Baek JY; Shin WS; Kim DB; Jang SW; Shin DI; Koh YS; Seo SM; Uhm JS; Kim TH; Kim CJ; Kim PJ; Chang K; Chung WS; Seung KB; Lee JM
Circ J; 2011; 75(7):1685-90. PubMed ID: 21576827
[TBL] [Abstract][Full Text] [Related]
15. Selenoprotein P in Myocardial Infarction With Cardiogenic Shock.
Büttner P; Obradovic D; Wunderlich S; Feistritzer HJ; Holzwirth E; Lauten P; Fuernau G; de Waha-Thiele S; Desch S; Thiele H
Shock; 2020 Jan; 53(1):58-62. PubMed ID: 30889044
[TBL] [Abstract][Full Text] [Related]
16. Advanced glycation end products decrease collagen I levels in fibroblasts from the vaginal wall of patients with POP via the RAGE, MAPK and NF-κB pathways.
Chen YS; Wang XJ; Feng W; Hua KQ
Int J Mol Med; 2017 Oct; 40(4):987-998. PubMed ID: 28849117
[TBL] [Abstract][Full Text] [Related]
17. High serum matrix metalloproteinase-9 level predict increased risk of in-hospital cardiac events in patients with type 2 diabetes and ST segment elevation myocardial infarction.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
Atherosclerosis; 2008 Jan; 196(1):365-371. PubMed ID: 17161405
[TBL] [Abstract][Full Text] [Related]
18. Enhanced proinflammatory response of mononuclear cells to in vitro LPS-challenge in patients with ventricular fibrillation in the setting of acute myocardial infarction.
Elmas E; Hölzer L; Lang S; Popp T; Kälsch T; Wolpert C; Brueckmann M; Borggrefe M
Cytokine; 2008 Aug; 43(2):138-42. PubMed ID: 18571935
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.
Fuernau G; Pöss J; Denks D; Desch S; Heine GH; Eitel I; Seiler S; de Waha S; Ewen S; Link A; Schuler G; Adams V; Böhm M; Thiele H
Crit Care; 2014 Dec; 18(6):713. PubMed ID: 25528363
[TBL] [Abstract][Full Text] [Related]
20. Activated protein C levels and outcome in patients with cardiogenic shock complicating acute myocardial infarction.
Fellner B; Rohla M; Jarai R; Smetana P; Freynhofer MK; Egger F; Zorn G; Weiss TW; Huber K; Geppert A
Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):348-358. PubMed ID: 26936869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
